ABSTRACT
In this study, we aimed to identify the myosin motor proteins that control trafficking at the Golgi complex. In addition to the known Golgi-associated myosins MYO6, MYO18A and MYH9 (myosin IIA), we identified MYO1C as a novel player at the Golgi in a human cell line. We demonstrate that depletion of MYO1C induces Golgi complex fragmentation and decompaction. MYO1C accumulates at dynamic structures around the Golgi complex that colocalize with Golgi-associated actin dots. MYO1C depletion leads to loss of cellular F-actin, and Golgi complex decompaction is also observed after inhibition or loss of the actin-related protein 2/3 complex, Arp2/3 (also known as ARPC). We show that the functional consequence of MYO1C depletion is a delay in the arrival of incoming transport carriers, both from the anterograde and retrograde routes. We propose that MYO1C stabilizes actin at the Golgi complex, facilitating the arrival of incoming transport carriers at the Golgi.
This article has an associated First Person interview with the first author of the paper.
Footnotes
Competing interests
The authors declare no competing or financial interests.
Author contributions
Conceptualization: A.C., B.G., K.S.; Methodology: A.C., A.Y., V.C., E.D.N., K.S.; Software: K.S.; Validation: K.S.; Formal analysis: A.C., R.K., K.S.; Investigation: A.C., K.S.; Resources: E.C., B.G., K.S.; Data curation: A.C., A.Y., R.K., V.C., A.L., K.S.; Writing - original draft: A.C., K.S.; Writing - review & editing: A.C., E.D.N., E.C., B.G., K.S.; Visualization: A.C., K.S.; Supervision: K.S.; Project administration: A.C., E.C., B.G., K.S.; Funding acquisition: E.C., B.G., K.S.
Funding
This work was supported by Labex CelTisPhyBio [ANR-10-LBX-0038] and Université de Recherche Paris Sciences et Lettres [ANR-10-IDEX-0001-02 PSL], as well as grants from Agence Nationale de la Recherche [#2010 BLAN 122902], the European Research Council [project 339847 ‘MYODYN’], Centre National de la Recherche Scientifique and Institut Curie.
Supplementary information
Supplementary information available online at http://jcs.biologists.org/lookup/doi/10.1242/jcs.225029.supplemental
- Received September 11, 2018.
- Accepted March 1, 2019.
- © 2019. Published by The Company of Biologists Ltd
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
2020 at The Company of Biologists
Despite the challenges of 2020, we were able to bring a number of long-term projects and new ventures to fruition. While we look forward to a new year, join us as we reflect on the triumphs of the last 12 months.
Mole – The Corona Files
"This is not going to go away, 'like a miracle.' We have to do magic. And I know we can."
Mole continues to offer his wise words to researchers on how to manage during the COVID-19 pandemic.
Cell scientist to watch – Christine Faulkner
In an interview, Christine Faulkner talks about where her interest in plant science began, how she found the transition between Australia and the UK, and shares her thoughts on virtual conferences.
Read & Publish participation extends worldwide
“The clear advantages are rapid and efficient exposure and easy access to my article around the world. I believe it is great to have this publishing option in fast-growing fields in biomedical research.”
Dr Jaceques Behmoaras (Imperial College London) shares his experience of publishing Open Access as part of our growing Read & Publish initiative. We now have over 60 institutions in 12 countries taking part – find out more and view our full list of participating institutions.
JCS and COVID-19
For more information on measures Journal of Cell Science is taking to support the community during the COVID-19 pandemic, please see here.
If you have any questions or concerns, please do not hestiate to contact the Editorial Office.